These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058 [TBL] [Abstract][Full Text] [Related]
3. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602 [TBL] [Abstract][Full Text] [Related]
4. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722 [TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma. Avilés A; Neri N; Fernández R; Huerta-Guzmán J; Nambo MJ Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1227-31. PubMed ID: 22172907 [TBL] [Abstract][Full Text] [Related]
6. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H; Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186 [TBL] [Abstract][Full Text] [Related]
7. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316 [TBL] [Abstract][Full Text] [Related]
8. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA; Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728 [TBL] [Abstract][Full Text] [Related]
9. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N; Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214 [TBL] [Abstract][Full Text] [Related]
10. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma. Avilés A; Nambo MJ; Neri N; Cleto S; Castañeda C; Huerta-Guzmàn J; Murillo E; Contreras M; Talavera A; González M Med Oncol; 2007; 24(1):85-9. PubMed ID: 17673816 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E; Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558 [TBL] [Abstract][Full Text] [Related]
12. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy. Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505 [TBL] [Abstract][Full Text] [Related]
13. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473 [TBL] [Abstract][Full Text] [Related]
15. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793 [TBL] [Abstract][Full Text] [Related]
16. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E; Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292 [TBL] [Abstract][Full Text] [Related]
17. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study. Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645 [TBL] [Abstract][Full Text] [Related]
18. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919 [TBL] [Abstract][Full Text] [Related]
19. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147 [TBL] [Abstract][Full Text] [Related]
20. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]